Communiqués Grace Therapeutics, Inc.

Actions

GRCE

US00439U1043

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 03/08/2026			Varia. 5j.	Varia. 1 janv.
2,080 ^USD	0,00%		-9,57%	-39,88%

28/07	Grace Therapeutics reçoit le compte rendu de sa réunion de type A avec la FDA et fait le point sur la formulation injectable de GTx-104 en phase clinique	CI
18/06	Grace Therapeutics fait le point sur le dépôt de sa demande d'autorisation de mise sur le marché pour le GTx-104 et publie les données de sécurité de l'essai de phase 3 STRIVE-ON	CI

Communiqués

28/07	Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration	AQ
18/06	Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update	AQ
18/06	Grace: Fiscal Q4 Earnings Snapshot	AQ
27/04	Grace Therapeutics : Overview	PU
23/04	Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104	AQ
14/04	Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026	AQ
19/03	Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences	AQ
25/02	Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference	AQ
13/02	Grace Therapeutics : Overview	PU
12/02	Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update	AQ
12/02	Grace: Fiscal Q3 Earnings Snapshot	AQ
30/11	Grace Therapeutics : Overview – Winter 2025	PU
17/11	Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference	AQ
13/11	Grace Therapeutics : Overview – Fall 2025	PU
13/11	Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update	AQ
11/11	Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting	AQ
23/10/25	Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review	AQ
22/09/25	Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting	AQ
18/09/25	Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104	AQ
04/09/25	Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference	AQ
27/08/25	Grace Therapeutics : Overview – Summer 2025	PU
27/08/25	Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104	AQ
13/08/25	Grace Therapeutics : Overview – Summer 2025	PU
12/08/25	Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update	AQ
12/08/25	Grace Therapeutics : Summary of July 2025 Amendment and Restatement to Code of Conduct and Ethics	PU